Observational Study on the long term prognosis in A Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Neoadjuvant and Adjuvant Chemotherapy with Encorafenib, Binimetinib Plus Cetuximab in Patients with Surgically Resectable BRAF V600E Mutant Colorectal Metastasis

Observational Study on the long term prognosis in A Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Neoadjuvant and Adjuvant Chemotherapy with Encorafenib, Binimetinib Plus Cetuximab in Patients with Surgically Resectable BRAF V600E Mutant Colorectal Metastasis - Observational Study in NEXUS Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050148

Enrollment

Registered

2023-01-27

Start date

2022-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with surgically resectable BRAF V600E mutant colorectal metastasis.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with resectable metastatic colorectal cancer with BRAF V600E mutation who were enrolled in the NEXUS study and consented to the secondary use of information obtained in the NEXUS study and consented to participate in the NEXUS study-observational study.

Exclusion criteria

Exclusion criteria: Patients whose consent has not been withdrawn will be included.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression free survival Disease-free survival Incidence of adverse events	—

Countries

Japan

Contacts

Public ContactShin kobayashi

National Cancer Center Hospital East Department of Hepatobiliary and Pancreatic Surgery

ymikamot@east.ncc.go.jp0471331111

Outcome results